根据患者和肿瘤特征分析新发晚期乳腺癌的发生率及特征——一项真实世界登记数据的回顾性分析
该回顾性分析基于PRAEGNANT转移性乳腺癌登记研究(NCT02338167)中947例初治转移性患者,纳入355例新发转移性乳腺癌(dnMBC,37.5%)。年龄较大和HER2阳性与dnMBC频率较高显著相关:<50岁、50-69岁、≥70岁患者dnMBC频率分别为22.7%、44.0%、57.6%;HER2阳性为49.1%,三阴性、luminal A-like、luminal B-like分别为21.9%、35.5%、37.6%。
要点
- 947例初治转移性乳腺癌患者中355例(37.5%)为新发转移性乳腺癌(dnMBC)。
- 年龄与dnMBC频率相关:<50岁22.7%、50-69岁44.0%、≥70岁57.6%。
- HER2阳性患者dnMBC频率49.1%,三阴性21.9%、luminal A-like 35.5%、luminal B-like 37.6%。
核心结论
- 年龄和乳腺癌亚型与初治转移性乳腺癌患者中新发转移(dnMBC)的频率相关。
- 纳入标准中关于年龄或乳腺癌亚型的规定可能影响所选患者人群中dnMBC的频率,并因此改变临床试验中对特定治疗存在继发耐药的患者数量。
研究设计与样本
- 本研究为对PRAEGNANT转移性乳腺癌登记研究(NCT02338167)前瞻性收集数据的回顾性分析。
- 初治转移性乳腺癌患者符合纳入条件,共识别947例患者,其中355例(37.5%)为新发转移性乳腺癌(dnMBC)。
- 比较患者和肿瘤特征与新发转移状态及原发灶无转移后的早期和晚期复发的关系。
主要发现
- 947例患者中355例(37.5%)为新发转移性乳腺癌(dnMBC)。
- 年龄较大与dnMBC频率较高显著相关:<50岁、50-69岁、≥70岁患者的dnMBC频率分别为22.7%、44.0%、57.6%。
- HER2阳性与dnMBC频率较高显著相关:HER2阳性患者初诊时dnMBC比例为49.1%,三阴性、luminal A-like、luminal B-like分别为21.9%、35.5%、37.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with de novo metastatic breast cancer (dnMBC) may have different clinical and pathological characteristics. In studies concerned with first-line metastatic patients, the proportion of these patients without secondary resistance mechanisms may have a large influence ont the study results. The aim of this study was to identify patient and tumor characteristics that are associated with dnMBC vs. recurrent MBC (rMBC). METHODS: This is a retrospective analysis of data prospectively collected in the PRAEGNANT metastatic breast cancer registry (NCT02338167). Firs line treated patients were eligible. Patient and tumor characteristics were compared with common disease and tumor characteristics relative to de novo metastatic status, as well as early and late recurrences after primary disease without metastases. RESULTS: Among the 947 patients identified, 355 were included with de novo metastatic disease (37.5%). Older age and HER2-positive disease were significantly associated with a higher frequency of dnMBC. Patients younger than 50, 50-69, or 70 years or older had dnMBC frequencies of 22.7%, 44.0%, and 57.6%, respectively. HER2-positive patients had dnMBC at initial presentation in 49.1% of cases, in comparison with 21.9%, 35.5%, and 37.6% in patients with triple-negative, luminal A-like and luminal B-like breast cancer, respectively. CONCLUSION: Age and breast cancer subtype are associated with the frequency of first-line MBC patients. Inclusion criteria concerning age or breast cancer subtype can influence the frequency of these patients in a selected patient population and can therefore modify the number of patients with secondary resistance to specific therapies in clinical trials.
引用
- Müller V, Hein A, Hartkopf AD, et al. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry. Eur J Cancer. 2022. PMID: 35728342. doi:10.1016/j.ejca.2022.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。